US regulator lifts clinical trial hold on Kura Oncology

The US regulator has cleared San Diego, USA-based precision medicine firm Kura Oncology (Nasdaq: KURA) to resume the KOMET-001 Phase Ib study of KO-539.

Kura is developing the candidate, a potent and selective menin inhibitor, for people with relapsed or refractory acute myeloid leukemia (AML).

The US Food and Drug Administration imposed a partial clinical hold in November 2021, after a patient death believed to be potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.